Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia

被引：13

作者：

Browning, Rebekah L. ^{[1
]}

Geyer, Susan M. ^{[2
]}

Johnson, Amy J. ^{[1
]}

Jelinek, Diane E. ^{[2
]}

Tschumper, Renee C. ^{[2
]}

Call, Timothy G. ^{[2
]}

Shanafelt, Tait D. ^{[2
]}

Zent, Clive S. ^{[2
]}

Bone, Nancy D. ^{[2
]}

Dewald, Gordon W. ^{[2
]}

Lin, Thomas S. ^{[1
]}

Heerema, Nyla A. ^{[1
]}

Grever, Michael R. ^{[1
]}

Kay, Neil E. ^{[2
]}

Byrd, John C. ^{[1
]}

Lucas, David M. ^{[1
]}

机构：

[1] Ohio State Univ, Columbus, OH 43210 USA

[2] Mayo Clin, Rochester, MN USA

来源：

LEUKEMIA RESEARCH | 2007年 / 31卷 / 12期

关键词：

chronic lymphocytic leukemia (CLL); TCL-1; prognostic factor; Pentostatin; chemoimmunotherapy;

D O I：

10.1016/j.leukres.2007.05.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TCL-1 expression is variable in CLL, and no study has examined its association with treatment response. We measured TCL-1 protein in CLL cells from 51 patients who then received pentostatin, cyclophosphamide, and rituximab. TCL-1 expression did not correlate with any pre-treatment characteristics. Lower TCL-1 levels were associated with higher probability of attaining flow cytometry-negative status post-treatment (52% versus 17%, p = 0.046). Trends toward improved complete remission rate (49% versus 19%, p = 0.064) and progression-free survival (medians: 33 versus 20 months, p = 0.199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted. Published by Elsevier Ltd.

引用

页码：1737 / 1740

页数：4

共 7 条

[1] Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression
Bichi, R
Shinton, SA
Martin, ES
Koval, A
Calin, GA
Cesari, R
Russo, G
Hardy, RR
Croce, CM
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (10) : 6955 - 6960
[2] TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state
Herling, M
Patel, KA
Khalili, J
Schlette, E
Kobayashi, R
Medeiros, LJ
Jones, D
[J]. LEUKEMIA, 2006, 20 (02) : 280 - 285
[3] Inhibition of Akt kinase activity by a peptide spanning the βA strand of the proto-oncogene TCL1
Hiromura, M
Okada, F
Obata, T
Auguin, D
Shibata, T
Roumestand, C
Noguchi, M
[J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (51) : 53407 - 53418
[4] Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Kay, Neil E.
Geyer, Susan M.
Call, Timothy G.
Shanafelt, Tait D.
Zent, Clive S.
Jelinek, Diane F.
Tschumper, Renee
Bone, Nancy D.
Dewald, Gordon W.
Lin, Thomas S.
Heerema, Nyla A.
Smith, Lisa
Grever, Michael R.
Byrd, John C.
[J]. BLOOD, 2007, 109 (02) : 405 - 411
[5] The protooncogene TCL1 is an Akt kinase coactivator
Laine, J
Künstle, G
Obata, T
Sha, M
Noguchi, M
[J]. MOLECULAR CELL, 2000, 6 (02) : 395 - 407
[6] The role of TCL1 in human T-cell leukemia
Pekarsky, Y
Hallas, C
Croce, CM
[J]. ONCOGENE, 2001, 20 (40) : 5638 - 5643
[7] Deregulated expression of TCL1 causes T cell leukemia in mice
Virgilio, L
Lazzeri, C
Bichi, R
Nibu, K
Narducci, MG
Russo, G
Rothstein, JL
Croce, CM
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) : 3885 - 3889

← 1 →